Newron Pharmaceuticals S.p.A. Stock
Stocks
NWRN
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
11:30:57 2026-11-10 EST
|
5-day change | 1st Jan Change | ||
| 9.180 CHF | -0.11% |
|
+2.46% | -61.51% |
| 10-22 | Newron Pharmaceuticals S.p.A. Completes Enrollment In Pivotal Phase 3 ENIGMA-TRS 1 Study | CI |
| 10-22 | Newron Pharmaceuticals Completes Enrollment for Schizophrenia Drug Late-stage Trial | MT |
| Market Cap | 212M 236M 195M 177M 335M 22.12B 344M 2.33B 930M 11.85B 885M 867M 37.46B | P/E 2026 * |
-6.31x | P/E 2027 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise Value | 226M 252M 208M 189M 358M 23.6B 368M 2.49B 993M 12.65B 945M 925M 39.98B | EV / Sales 2026 * |
27.1x | EV / Sales 2027 * | 3.97x |
| Free-Float |
87.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NWRN | Delayed | |
Xetra
| NP5 | Delayed | |
|
Tradegate
| NP5 | Real-time | |
|
CBOE
| 0QOI | Real-time | |
|
Deutsche Boerse AG
| NP5 | Delayed | |
|
Boerse Muenchen
| NP5 | Real-time | |
|
Börse Stuttgart
| NP5 | Delayed |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | -0.11% | ||
| 1 week | +2.46% | ||
| Current month | +2.00% | ||
| 1 month | +20.95% | ||
| 3 months | -22.86% | ||
| 6 months | -32.50% | ||
| Current year | -61.51% |
| 1 week | 8.47 |  | 9.44 |
| 1 month | 7.4 | | 9.48 |
| Current year | 5.72 | | 31.85 |
| 1 year | 5.72 | | 31.85 |
| 3 years | 4.09 | | 31.85 |
| 5 years | 1.01 | | 31.85 |
| 10 years | 0.9 | | 31.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 2012-05-14 |
Roberto Galli
DFI | Director of Finance/CFO | - | 2011-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 2012-05-14 |
Gillian Dines
BRD | Director/Board Member | - | 2023-03-31 |
Margarita Chavez
BRD | Director/Board Member | - | 2024-04-16 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/12/26 | Buy | Chief Executive Officer | 2,000 | 0.0096% | ||
| 8/11/26 | Buy | Chief Technology Officer | 582 | 0.0028% | ||
| 8/10/26 | Buy | Chief Technology Officer | 1,418 | 0.0068% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.11% | +2.46% | -35.62% | +85.45% | 238M | |
| +0.01% | +11.10% | +60.83% | +70.43% | 68.22B | |
| +1.22% | +9.56% | +15.97% | +90.23% | 59.82B | |
| +0.24% | +1.35% | +23.78% | +97.55% | 56.07B | |
| +1.60% | +19.44% | +28.80% | +112.95% | 47.67B | |
| -1.32% | +4.78% | +29.15% | +40.40% | 45.95B | |
| -3.54% | -0.60% | +207.76% | +879.50% | 43.29B | |
| -3.33% | +6.90% | +22.78% | +48.07% | 35.66B | |
| -2.19% | -3.71% | +90.94% | +66.33% | 34.73B | |
| -2.54% | +0.08% | +45.49% | -0.90% | 25.6B | |
| Average | -1.00% | +5.62% | +48.99% | +149.00% | 42B | |
| Weighted average by Cap. | -0.74% | +5.71% | +55.77% | +155.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.32M 9.28M 7.67M 6.97M 13.18M 870M 13.55M 91.83M 36.59M 466M 34.83M 34.09M 1.47B | 57.9M 64.56M 53.36M 48.46M 91.71M 6.05B 94.27M 639M 255M 3.24B 242M 237M 10.25B |
| Net income | -32.8M -36.58M -30.23M -27.45M -51.96M -3.43B -53.41M -362M -144M -1.84B -137M -134M -5.81B | 9.39M 10.47M 8.65M 7.86M 14.88M 982M 15.29M 104M 41.29M 526M 39.3M 38.47M 1.66B |
| Net Debt | 14.21M 15.85M 13.1M 11.89M 22.51M 1.49B 23.14M 157M 62.47M 796M 59.47M 58.2M 2.52B | 18.13M 20.22M 16.71M 15.18M 28.72M 1.9B 29.52M 200M 79.72M 1.02B 75.88M 74.27M 3.21B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-10 | CHF 9.180 | -0.11% | 38,052 |
| 26-11-09 | CHF 9.190 | +4.08% | 16,775 |
| 26-11-06 | CHF 8.830 | +0.91% | 34,239 |
| 26-11-05 | CHF 8.750 | -6.91% | 81,294 |
| 26-11-04 | CHF 9.400 | +4.91% | 91,918 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NWRN Stock
Select your edition
All financial news and data tailored to specific country editions
